Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Thrombosis Research
|
May 3, 2021
Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis
Matthew Moll, Rebecca L Zon, Katelyn W Sylvester, et al.
Blood Advances
|
February 19, 2025
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Reid Shaw, James J Yoon, Hannah Johnston, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia
Emma-Jayne Minihane, Leah Krotee, Jason Wu, et al.
American Journal of Hematology
|
May 16, 2024
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Haematologica
|
January 29, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities
Leora Boussi, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Advances
|
June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Blood Neoplasia
|
September 15, 2025
Response and outcomes of patients with <i>IDH1/2-</i> mutated accelerated/blast-phase myeloproliferative neoplasms
Leah A Goldberg, James J Yoon, Hannah Johnston, et al.
Blood Neoplasia
|
March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics
Luis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Advances
|
May 13, 2024
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
Anand A Patel, James J Yoon, Hannah Johnston, et al.
Bone Marrow Transplantation
|
November 6, 2024
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Gege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Thrombosis Research
|
May 3, 2021
Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis
Matthew Moll, Rebecca L Zon, Katelyn W Sylvester, et al.
Blood Advances
|
February 19, 2025
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Reid Shaw, James J Yoon, Hannah Johnston, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia
Emma-Jayne Minihane, Leah Krotee, Jason Wu, et al.
American Journal of Hematology
|
May 16, 2024
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Haematologica
|
January 29, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities
Leora Boussi, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Advances
|
June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Blood Neoplasia
|
September 15, 2025
Response and outcomes of patients with <i>IDH1/2-</i> mutated accelerated/blast-phase myeloproliferative neoplasms
Leah A Goldberg, James J Yoon, Hannah Johnston, et al.
Blood Neoplasia
|
March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics
Luis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Advances
|
May 13, 2024
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
Anand A Patel, James J Yoon, Hannah Johnston, et al.
Bone Marrow Transplantation
|
November 6, 2024
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Gege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Page
of 5